The company is targeting a very large potential market.

The long term picture and the potential for the company to be acquired is probably more relevant to the share price at this point.

No company has seriously looked at the SMB market, which has a huge potential.

However, the number of potential acquirers could be limited and would likely involve a European drug company.

We think that investor speculation on a potential take-over of the company could keep shares in the mid-$20s range.

The company is doing this because it's clearly trying to be more attractive (to potential buyers).